Login to Your Account



In The Clinic NEWS

Positive data from dual phase III studies of oral sarecycline in moderate to severe acne poised originator Paratek Pharmaceuticals Inc. to earn a $5 million milestone payment from partner Allergan plc.

PERTH, Australia – Australian cell therapy developer Mesoblast Ltd. is moving to phase III trials with its allogeneic mesenchymal precursor cell therapy to treat chronic low back pain.

Adding the investigational advanced breast cancer candidate, abemaciclib, to the already-approved drug fulvestrant, reduced the risk of disease worsening or death for women with HER2-negative disease more than adding a placebo.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: